Director exit arrangements

Source: RNS
RNS Number : 2828D
ReNeuron Group plc
02 March 2022


ReNeuron Group plc

("ReNeuron" or the "Company")


Director exit arrangements 


ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that pursuant to the departure of its former Chief Executive Officer, Olav Hellebø, certain exit arrangements have been entered into which are deemed to be related party arrangements under the AIM Rules for Companies.

The Company has agreed a payment in lieu of notice, and a further c.£29k outside of his contractual terms, to cover pension and other benefits. In addition, under the terms of the Company's option plans, Mr Hellebø will retain his vested and unvested options, save for 331,382 options which have been deemed to have lapsed. Further details on Mr Hellebø's options are set out in the Company's 2021 annual report and subsequent award announcements, and he retains options over 1,180,553 outstanding options of which 165,848 are either already exercisable or subject to a holding period and with an exercise price below the current share price.

The above arrangements constitute a related party transaction under the AIM Rules for Companies.  The directors, excluding Olav Hellebø who is no longer a director, consider, having consulted with the Company's nominated adviser, Stifel Nicolaus Europe Limited, that the terms of the transaction are fair and reasonable insofar as the Company's shareholders are concerned. 







Iain Ross, Chairman

Via Walbrook PR

Catherine Isted, Chief Financial Officer




Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600




Allenby Capital Limited (Joint Broker)

+44 (0)20 3328 5656

James Reeve/George Payne (Corporate Finance)


Stefano Aquilino (Sales & Corporate Broking)




Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or

Paul McManus/Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654



About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.


ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.


The Company has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-licence both these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.